SCHEMBL20504988

SCHEMBL20504988

Cc1c(F)c(F)cc2[nH]c(C(=O)O)cc12

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EIF4A3 P38919 4/20 0.56
IDO1 P14902 7/20 0.46
TDO2 P48775 7/20 0.46
GRIN1 Q05586 1/20 0.46
RHEB Q15382 3/20 0.44
PIN1 Q13526 1/20 0.42
GPR35 Q9HC97 1/20 0.42
KDM4E B2RXH2 1/20 0.42
PDPK1 O15530 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42
APEX1 P27695 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
DAO P14920 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20505517 0.85 EIF4A3 (0.41) EIF4A3IDO1TDO2RHEB
SCHEMBL29946251 0.84 EIF4A3 (0.57) EIF4A3IDO1TDO2GRIN1RHEB
SCHEMBL22395159 0.84 EIF4A3 (0.57) EIF4A3IDO1TDO2GRIN1RHEB
SCHEMBL20505161 0.83 ULK1 (0.47) EIF4A3IDO1TDO2
SCHEMBL3100612 0.80 HRH4 (0.60) EIF4A3IDO1TDO2GRIN1RHEB
SCHEMBL23147766 0.79 EIF4A3 (0.64) EIF4A3IDO1TDO2GRIN1RHEB
SCHEMBL31416338 0.78 EIF4A3 (0.58) EIF4A3IDO1TDO2GRIN1RHEB
SCHEMBL13174690 0.76 EIF4A3 (0.52) EIF4A3IDO1TDO2GRIN1RHEB
SCHEMBL1144892 0.75 EIF4A3 (0.63) EIF4A3IDO1TDO2GRIN1RHEB
SCHEMBL29655546 0.75 EIF4A3 (0.63) EIF4A3IDO1TDO2GRIN1RHEB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3928836-B1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-09-18 EP disclosed
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-18 US disclosed
EP-3377483-B9 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-08-03 EP disclosed
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-06-09 US disclosed
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2022-02-08 US disclosed
EP-3928836-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2021-12-29 EP disclosed
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2020-09-17 US disclosed
EP-3377483-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2018-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 EIF4A3 1494/4885IDO1 51/4885TDO2 499/4885
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 EIF4A3 1494/4885IDO1 51/4885TDO2 499/4885
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 EIF4A3 1494/4885IDO1 51/4885TDO2 499/4885
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 EIF4A3 1494/4885IDO1 51/4885TDO2 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.